Long-term clinical outcome of 103 patients with acromegaly after pituitary surgery
Authors' conclusion
About half of the patients had biochemical control of acromegaly 1-year post-surgery. Treatment patterns reflected the complexity of post-surgical management and provided an overview of the long-term clinical progression in patients with acromegaly following pituitary surgery.
Study context
- Population
- Patients with acromegaly who underwent surgery for a GH-producing pituitary adenoma at Sahlgrenska University Hospital, 1994–2019
- Participants
- 103 patients111 surgeries
- Outcome
- Path of treatment and long-term outcome of acromegaly after pituitary surgery
Methodological detailssingle-centre, Medical records reviewed from diagnosis to end of study (November 2022)
- Single-centre
- Medical records reviewed from diagnosis to end of study (November 2022)
Main finding
As reported in the abstract
Biochemical control of acromegaly at 1-year post-surgery (evaluable patients)
50%
No additional medication for acromegaly after surgery until end of follow-up (of 96 with follow-up >1 year)
53
51.5%
Received medical therapy, diagnosis to end of follow-up
53 patients
Treated with radiotherapy, diagnosis to end of follow-up
7
Observational data: associations, not effects.
Further findings
- Lesions identified as macroadenoma
- 76 (76.8%)
Safety
Surgical complications and new pituitary hormone deficiency or SIADH · post-surgical follow-up until discharge
- Surgical complications and new pituitary hormone deficiency or syndrome of inappropriate antidiuretic hormone secretion
- 37% of cases
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →